The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Raibizumab Biosimilars Market Research Report 2025

Global Raibizumab Biosimilars Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1681337

No of Pages : 115

Ask Your Query
Synopsis
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
Global Raibizumab Biosimilars market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Raibizumab Biosimilars market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Raibizumab Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Novartis
Genentech
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius
Segment by Type
AMD
CNV
DME
Segment by Application
ARMD
Diabetic Retinopathy
Macular Edema
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Raibizumab Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index
1 Raibizumab Biosimilars Market Overview
1.1 Product Overview and Scope of Raibizumab Biosimilars
1.2 Raibizumab Biosimilars Segment by Type
1.2.1 Global Raibizumab Biosimilars Market Value Comparison by Type (2023-2029)
1.2.2 AMD
1.2.3 CNV
1.2.4 DME
1.3 Raibizumab Biosimilars Segment by Application
1.3.1 Global Raibizumab Biosimilars Market Value by Application: (2023-2029)
1.3.2 ARMD
1.3.3 Diabetic Retinopathy
1.3.4 Macular Edema
1.4 Global Raibizumab Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Raibizumab Biosimilars Revenue 2018-2029
1.4.2 Global Raibizumab Biosimilars Sales 2018-2029
1.4.3 Global Raibizumab Biosimilars Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Raibizumab Biosimilars Market Competition by Manufacturers
2.1 Global Raibizumab Biosimilars Sales Market Share by Manufacturers (2018-2023)
2.2 Global Raibizumab Biosimilars Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Raibizumab Biosimilars Average Price by Manufacturers (2018-2023)
2.4 Global Raibizumab Biosimilars Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Raibizumab Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Raibizumab Biosimilars, Product Type & Application
2.7 Raibizumab Biosimilars Market Competitive Situation and Trends
2.7.1 Raibizumab Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Raibizumab Biosimilars Players Market Share by Revenue
2.7.3 Global Raibizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Raibizumab Biosimilars Retrospective Market Scenario by Region
3.1 Global Raibizumab Biosimilars Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Raibizumab Biosimilars Global Raibizumab Biosimilars Sales by Region: 2018-2029
3.2.1 Global Raibizumab Biosimilars Sales by Region: 2018-2023
3.2.2 Global Raibizumab Biosimilars Sales by Region: 2024-2029
3.3 Global Raibizumab Biosimilars Global Raibizumab Biosimilars Revenue by Region: 2018-2029
3.3.1 Global Raibizumab Biosimilars Revenue by Region: 2018-2023
3.3.2 Global Raibizumab Biosimilars Revenue by Region: 2024-2029
3.4 North America Raibizumab Biosimilars Market Facts & Figures by Country
3.4.1 North America Raibizumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Raibizumab Biosimilars Sales by Country (2018-2029)
3.4.3 North America Raibizumab Biosimilars Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Raibizumab Biosimilars Market Facts & Figures by Country
3.5.1 Europe Raibizumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Raibizumab Biosimilars Sales by Country (2018-2029)
3.5.3 Europe Raibizumab Biosimilars Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Raibizumab Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Raibizumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Raibizumab Biosimilars Sales by Country (2018-2029)
3.6.3 Asia Pacific Raibizumab Biosimilars Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Raibizumab Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Raibizumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Raibizumab Biosimilars Sales by Country (2018-2029)
3.7.3 Latin America Raibizumab Biosimilars Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Raibizumab Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Raibizumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Raibizumab Biosimilars Sales by Country (2018-2029)
3.8.3 Middle East and Africa Raibizumab Biosimilars Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Raibizumab Biosimilars Sales by Type (2018-2029)
4.1.1 Global Raibizumab Biosimilars Sales by Type (2018-2023)
4.1.2 Global Raibizumab Biosimilars Sales by Type (2024-2029)
4.1.3 Global Raibizumab Biosimilars Sales Market Share by Type (2018-2029)
4.2 Global Raibizumab Biosimilars Revenue by Type (2018-2029)
4.2.1 Global Raibizumab Biosimilars Revenue by Type (2018-2023)
4.2.2 Global Raibizumab Biosimilars Revenue by Type (2024-2029)
4.2.3 Global Raibizumab Biosimilars Revenue Market Share by Type (2018-2029)
4.3 Global Raibizumab Biosimilars Price by Type (2018-2029)
5 Segment by Application
5.1 Global Raibizumab Biosimilars Sales by Application (2018-2029)
5.1.1 Global Raibizumab Biosimilars Sales by Application (2018-2023)
5.1.2 Global Raibizumab Biosimilars Sales by Application (2024-2029)
5.1.3 Global Raibizumab Biosimilars Sales Market Share by Application (2018-2029)
5.2 Global Raibizumab Biosimilars Revenue by Application (2018-2029)
5.2.1 Global Raibizumab Biosimilars Revenue by Application (2018-2023)
5.2.2 Global Raibizumab Biosimilars Revenue by Application (2024-2029)
5.2.3 Global Raibizumab Biosimilars Revenue Market Share by Application (2018-2029)
5.3 Global Raibizumab Biosimilars Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Roche Raibizumab Biosimilars Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novartis Raibizumab Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Genentech
6.3.1 Genentech Corporation Information
6.3.2 Genentech Description and Business Overview
6.3.3 Genentech Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Genentech Raibizumab Biosimilars Product Portfolio
6.3.5 Genentech Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Raibizumab Biosimilars Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Sartorius
6.5.1 Sartorius Corporation Information
6.5.2 Sartorius Description and Business Overview
6.5.3 Sartorius Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sartorius Raibizumab Biosimilars Product Portfolio
6.5.5 Sartorius Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Eli Lilly Raibizumab Biosimilars Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bayer Raibizumab Biosimilars Product Portfolio
6.7.5 Bayer Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Corporation Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Amgen Raibizumab Biosimilars Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 PlantForm
6.9.1 PlantForm Corporation Information
6.9.2 PlantForm Description and Business Overview
6.9.3 PlantForm Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.9.4 PlantForm Raibizumab Biosimilars Product Portfolio
6.9.5 PlantForm Recent Developments/Updates
6.10 PharmaPraxis
6.10.1 PharmaPraxis Corporation Information
6.10.2 PharmaPraxis Description and Business Overview
6.10.3 PharmaPraxis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.10.4 PharmaPraxis Raibizumab Biosimilars Product Portfolio
6.10.5 PharmaPraxis Recent Developments/Updates
6.11 Samsung Bioepis
6.11.1 Samsung Bioepis Corporation Information
6.11.2 Samsung Bioepis Raibizumab Biosimilars Description and Business Overview
6.11.3 Samsung Bioepis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Samsung Bioepis Raibizumab Biosimilars Product Portfolio
6.11.5 Samsung Bioepis Recent Developments/Updates
6.12 Centus
6.12.1 Centus Corporation Information
6.12.2 Centus Raibizumab Biosimilars Description and Business Overview
6.12.3 Centus Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Centus Raibizumab Biosimilars Product Portfolio
6.12.5 Centus Recent Developments/Updates
6.13 Cadila Pharmaceuticals
6.13.1 Cadila Pharmaceuticals Corporation Information
6.13.2 Cadila Pharmaceuticals Raibizumab Biosimilars Description and Business Overview
6.13.3 Cadila Pharmaceuticals Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Cadila Pharmaceuticals Raibizumab Biosimilars Product Portfolio
6.13.5 Cadila Pharmaceuticals Recent Developments/Updates
6.14 Dr Reddy's
6.14.1 Dr Reddy's Corporation Information
6.14.2 Dr Reddy's Raibizumab Biosimilars Description and Business Overview
6.14.3 Dr Reddy's Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Dr Reddy's Raibizumab Biosimilars Product Portfolio
6.14.5 Dr Reddy's Recent Developments/Updates
6.15 Aurobindo Pharma
6.15.1 Aurobindo Pharma Corporation Information
6.15.2 Aurobindo Pharma Raibizumab Biosimilars Description and Business Overview
6.15.3 Aurobindo Pharma Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Aurobindo Pharma Raibizumab Biosimilars Product Portfolio
6.15.5 Aurobindo Pharma Recent Developments/Updates
6.16 Biocad
6.16.1 Biocad Corporation Information
6.16.2 Biocad Raibizumab Biosimilars Description and Business Overview
6.16.3 Biocad Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Biocad Raibizumab Biosimilars Product Portfolio
6.16.5 Biocad Recent Developments/Updates
6.17 MAbxience
6.17.1 MAbxience Corporation Information
6.17.2 MAbxience Raibizumab Biosimilars Description and Business Overview
6.17.3 MAbxience Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.17.4 MAbxience Raibizumab Biosimilars Product Portfolio
6.17.5 MAbxience Recent Developments/Updates
6.18 Hetero
6.18.1 Hetero Corporation Information
6.18.2 Hetero Raibizumab Biosimilars Description and Business Overview
6.18.3 Hetero Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Hetero Raibizumab Biosimilars Product Portfolio
6.18.5 Hetero Recent Developments/Updates
6.19 Biocon
6.19.1 Biocon Corporation Information
6.19.2 Biocon Raibizumab Biosimilars Description and Business Overview
6.19.3 Biocon Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Biocon Raibizumab Biosimilars Product Portfolio
6.19.5 Biocon Recent Developments/Updates
6.20 Kirin Biologics
6.20.1 Kirin Biologics Corporation Information
6.20.2 Kirin Biologics Raibizumab Biosimilars Description and Business Overview
6.20.3 Kirin Biologics Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Kirin Biologics Raibizumab Biosimilars Product Portfolio
6.20.5 Kirin Biologics Recent Developments/Updates
6.21 Mylan
6.21.1 Mylan Corporation Information
6.21.2 Mylan Raibizumab Biosimilars Description and Business Overview
6.21.3 Mylan Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Mylan Raibizumab Biosimilars Product Portfolio
6.21.5 Mylan Recent Developments/Updates
6.22 BeiGene
6.22.1 BeiGene Corporation Information
6.22.2 BeiGene Raibizumab Biosimilars Description and Business Overview
6.22.3 BeiGene Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.22.4 BeiGene Raibizumab Biosimilars Product Portfolio
6.22.5 BeiGene Recent Developments/Updates
6.23 Innovent
6.23.1 Innovent Corporation Information
6.23.2 Innovent Raibizumab Biosimilars Description and Business Overview
6.23.3 Innovent Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Innovent Raibizumab Biosimilars Product Portfolio
6.23.5 Innovent Recent Developments/Updates
6.24 Qilu Pharmaceutical
6.24.1 Qilu Pharmaceutical Corporation Information
6.24.2 Qilu Pharmaceutical Raibizumab Biosimilars Description and Business Overview
6.24.3 Qilu Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Qilu Pharmaceutical Raibizumab Biosimilars Product Portfolio
6.24.5 Qilu Pharmaceutical Recent Developments/Updates
6.25 Hengrui Pharmaceuticals
6.25.1 Hengrui Pharmaceuticals Corporation Information
6.25.2 Hengrui Pharmaceuticals Raibizumab Biosimilars Description and Business Overview
6.25.3 Hengrui Pharmaceuticals Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Hengrui Pharmaceuticals Raibizumab Biosimilars Product Portfolio
6.25.5 Hengrui Pharmaceuticals Recent Developments/Updates
6.26 Hisun Pharmaceutical
6.26.1 Hisun Pharmaceutical Corporation Information
6.26.2 Hisun Pharmaceutical Raibizumab Biosimilars Description and Business Overview
6.26.3 Hisun Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.26.4 Hisun Pharmaceutical Raibizumab Biosimilars Product Portfolio
6.26.5 Hisun Pharmaceutical Recent Developments/Updates
6.27 TOT BIOPHARM
6.27.1 TOT BIOPHARM Corporation Information
6.27.2 TOT BIOPHARM Raibizumab Biosimilars Description and Business Overview
6.27.3 TOT BIOPHARM Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.27.4 TOT BIOPHARM Raibizumab Biosimilars Product Portfolio
6.27.5 TOT BIOPHARM Recent Developments/Updates
6.28 Luye Pharmaceutical
6.28.1 Luye Pharmaceutical Corporation Information
6.28.2 Luye Pharmaceutical Raibizumab Biosimilars Description and Business Overview
6.28.3 Luye Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.28.4 Luye Pharmaceutical Raibizumab Biosimilars Product Portfolio
6.28.5 Luye Pharmaceutical Recent Developments/Updates
6.29 Henlius
6.29.1 Henlius Corporation Information
6.29.2 Henlius Raibizumab Biosimilars Description and Business Overview
6.29.3 Henlius Raibizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.29.4 Henlius Raibizumab Biosimilars Product Portfolio
6.29.5 Henlius Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Raibizumab Biosimilars Industry Chain Analysis
7.2 Raibizumab Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Raibizumab Biosimilars Production Mode & Process
7.4 Raibizumab Biosimilars Sales and Marketing
7.4.1 Raibizumab Biosimilars Sales Channels
7.4.2 Raibizumab Biosimilars Distributors
7.5 Raibizumab Biosimilars Customers
8 Raibizumab Biosimilars Market Dynamics
8.1 Raibizumab Biosimilars Industry Trends
8.2 Raibizumab Biosimilars Market Drivers
8.3 Raibizumab Biosimilars Market Challenges
8.4 Raibizumab Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock